First paediatric isoniazid/rifampicin 50/75 dispersible tablet prequalified
M
On 31 August 2017, WHO Prequalification Team - Medicines (PQTm) added the below new product to its prequalified list:
News
WHO Prequalifies key treatment for children with TB
M
WHO has just prequalified a two-pills-in-one paediatric medicine that is critical for the continuation phase of the six-month treatment required to cure tuberculosis (TB).
Key performance indicators for WHO prequalification
M
In the interest of monitoring performance and increasing its capacity to report on that performance to its many stakeholders, the WHO Prequalification Team has developed new key performance indicat
First generic sofosbuvir prequalified
M
WHO Prequalification Team - Medicines (PQTm) added the below new product to its prequalified list:
Shanghai Desano’s lamivudine/zidovudine tablet prequalified
M
WHO Prequalification Team - Medicines (PQTm) added the below new product to its prequalified list:
Hetero's ritonavir 100mg tablet prequalified
M
WHO Prequalification Team - Medicines (PQTm) added the below new product to its prequalified list:
Hetero's moxifloxacin 400mg tablet prequalified
M
WHO Prequalification Team - Medicines (PQTm) added the below new products to its prequalified list:
Newly prequalified Quality Control Laboratories (QCLs)
M
New additions to the List of Prequalified Quality Control Laboratories (QCL):
Newly prequalified Active Pharmaceutical Ingredient (API)
M
Protionamide (WHOAPI-284) manufactured by Mylan Laboratories Ltd ha
First kanamycin injection prequalified
M
WHO Prequalification Team - Medicines (PQTm) added the below new products to its prequalified list:
Cipla's artemether/lumefantrine tablet range prequalified
M
WHO Prequalification Team - Medicines (PQTm) added the below new products to its prequalified list:
Cipla's 20mg/120mg dispersible tablet prequalified
M
WHO Prequalification Team - Medicines (PQTm) added the below new products to its prequalified list:
First Etravirine Active Pharmaceutical Ingredient (API) prequalified
M
Etravirine (WHOAPI-280) manufactured by Mylan Laboratories Ltd has
First generic magnesium injection prequalified
M
WHO Prequalification Team: medicines (PQTm) added the below new products to its prequalified list:
First generic oxytocin prequalified
M
WHO Prequalification Team: medicines (PQTm) added the below new products to its prequalified list
First generic streptomycin injection prequalified
M
WHO Prequalification Team: medicines (PQTm) added the below new products to its prequalified list:
Sino-Implant (II) (levonorgestrel contraceptive implant) prequalified
M
WHO Prequalification Team - Medicines (PQTm) added the below new products to its prequalified list:
Second abacavir 60mg dispersible prequalified
M
WHO Prequalification Team - Medicines (PQTm) added the below new products to its prequalified list:
Strides Shasun' cycloserine capsule prequalified
M
WHO Prequalification Team - Medicines (PQTm) added the below new products to its prequalified list
Hetero's efavirenz/lamivudine/tenofovir tablet prequalified
M
WHO Prequalification Team - Medicines (PQTm) added the below new products to its prequalified list:
Mylan's acyclovir tablets 200mg and 400mg prequalified
M
WHO Prequalification Team - Medicines (PQTm) added the below new products to its prequalified list:
Newly prequalified Active Pharmaceutical Ingredients (APIs)
M
Pyrimethamine (WHOAPI-278) and sulfadoxine (WHOAPI-279) manufactured by Gu
First dispersible paediatric ethionamide tablet prequalified
M
WHO Prequalification Team - Medicines (PQTm) added the below new products to its prequalified list
15th Invitation to manufacturers and suppliers of medicinal products for HIV infections and related diseases to submit and Expression of Interest (EOI) for product evaluation to the WHO Prequalification Team: medicines
M
The following products were added:
- Lamivudine/Abacavir/Dolutegravir, tablet 30mg/60mg/5mg dispersible
Newly prequalified Active Pharmaceutical Ingredients (APIs)
M
WHO Prequalification wishes to announce the prequalification of three new prequalified APIs, namely:
WHO to begin pilot prequalification of biosimilars for cancer treatment
M
This year WHO will launch a pilot project for prequalifying biosimilar medicines, a step towards making some of the most expensive treatments for cancer more widely available in low- and midd
Eritrea joins the collaborative registration procedure
M
Click here for detailed information on the Collaborative
Newly Prequalified Active Pharmaceutical Ingredients (APIs)
M
Artemether (WHOAPI-268) manufactured by Chongqing Holley Wuling Mountain Pharmaceutical Co Ltd and Darunavir (ethanolate) (WHOAPI-214) ma